These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 31285291)

  • 1. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
    Dávila I; Quirce S; Olaguibel JM
    J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
    Kyriakopoulos C; Gogali A; Markozannes G; Kostikas K
    Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 38657997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised medicine in asthma: from curative to preventive medicine.
    Guilleminault L; Ouksel H; Belleguic C; Le Guen Y; Germaud P; Desfleurs E; Leroyer C; Magnan A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28049124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
    Santus P; Saad M; Damiani G; Patella V; Radovanovic D
    Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 severe asthma: pathophysiology and treatment with biologics.
    Pelaia C; Melhorn J; Hinks TS; Couillard S; Vatrella A; Pelaia G; Pavord ID
    Expert Rev Respir Med; 2024 Jul; 18(7):485-498. PubMed ID: 38994712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are biologics effective on lung hyperinflation in patients with resistant asthma?
    Goto T; Hernandez CG; Tsujimoto Y; Kitagawa T
    Respir Med; 2024 Jun; 227():107652. PubMed ID: 38697230
    [No Abstract]   [Full Text] [Related]  

  • 12. Type-2 severe asthma comorbidities in the era of biologics: time to rethink clinical response?
    Portacci A; Dragonieri S; Carpagnano GE
    Expert Rev Respir Med; 2024 May; 18(5):249-253. PubMed ID: 38845590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.
    Rogers L; Jesenak M; Bjermer L; Hanania NA; Seys SF; Diamant Z
    Respir Med; 2023 Nov; 218():107414. PubMed ID: 37776915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
    Samitas K; Delimpoura V; Zervas E; Gaga M
    Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Treatments for Asthma.
    Huang J; Pansare M
    Pediatr Clin North Am; 2019 Oct; 66(5):925-939. PubMed ID: 31466682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.
    Adir Y; Humbert M; Saliba W
    J Allergy Clin Immunol; 2021 Aug; 148(2):361-367.e13. PubMed ID: 34144110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies and opportunities in severe asthma.
    Humbert M; Busse W; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma.
    Blaiss MS; Castro M; Chipps BE; Zitt M; Panettieri RA; Foggs MB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):533-540. PubMed ID: 29103801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological management of asthma in adults: 2023 update.
    Matera MG; Rinaldi B; Annibale R; De Novellis V; Cazzola M
    Expert Opin Pharmacother; 2024 Mar; 25(4):383-393. PubMed ID: 38497368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.